Navigation Links
Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results
Date:8/2/2011

MINNEAPOLIS, Aug. 2, 2011 /PRNewswire/ -- Techne Corporation's (NASDAQ: TECH) financial results for the fourth quarter and fiscal year ended June 30, 2011 include the following highlights:


  • Fourth quarter earnings grew 9.4% to $28.3 million or $.76 per diluted share.  Earnings for the quarter grew 21.2% to $31.6 million or $.85 per diluted share when adjusted for intangible asset amortization, costs recognized upon the sale of inventory that was written up to fair value as part of the acquisitions completed in the quarter and professional and other acquisition related costs. Fiscal year earnings grew 2.3% to $112 million or $3.02 per diluted share. Earnings for the fiscal year grew 9.9% to $116 million or $3.13 per diluted share when adjusted for the above identified items and the tax benefit in fiscal 2010 from repatriation of cash.


  • Net sales as reported grew 17.0% to $78.0 million for the quarter. Organic sales grew 6.5% in the quarter.Net sales as reported grew 7.8% to $290 million for the fiscal year. Organic sales grew 5.9% in the fiscal year.  Consolidated net earnings for the quarter and fiscal year ended June 30, 2011 were impacted by the acquisition of Boston Biochem, Inc. (Boston Biochem) on April 1, 2011 and Tocris Holdings Limited (Tocris) on April 28, 2011, including the cost recognized upon the sale of inventory that was written up to fair value as part of the acquisitions, increased amortization of acquired  intangible assets, professional fees and other costs to complete the transactions and an increase in the effective tax rate as a result of certain acquisition costs not being deductible.  Increased sales and foreign exchange transaction gains also helped to improve earnings.  Results for the prior fiscal year included a $4.7 million tax benefit, equating to $.12 per share, from a foreign exchange tax loss on Techne's repatriation of 50 million pounds sterling from R&D Systems Europe to its U.S. based parent.

    Consolidated net sales for the quarter and fiscal year ended June 30, 2011 include $4.7 million of sales from the acquired companies.  A weaker U.S. dollar as compared to foreign currencies improved sales by $2.3 million and $466,000 in the quarter and fiscal year ended June 30, 2011, respectively, from the comparable prior-year periods.

    As a result of the acquisitions described above, the Company has revised its segment reporting and will include the operations of R&D Systems' Biotechnology Division, R&D Systems Europe, Tocris, R&D Systems China, BiosPacific and Boston Biochem in its Biotechnology segment. R&D Systems' Hematology Division operations will continue to be reported as the Company's Hematology segment.

    Biotechnology segment net sales were $73.0 million for the quarter ended June 30, 2011, an increase of 17.3% from $62.3 million for the quarter ended June 30, 2010.  Biotechnology net sales were $270 million for the fiscal year ended June 30, 2011, an increase of 7.8% from $251 million for the fiscal year ended June 30, 2010.  Biotechnology sales growth was 6.1% and 5.8% for the quarter and fiscal year ended June 30, 2011, respectively, if the sales from the acquisitions and foreign currency benefit are excluded.

    Customer sales growth for the Biotechnology segment from the same prior-year periods included:Period ended June 30, 2011Quarter

    Fiscal YearR&D Systems Biotechnology Division:Industrial, pharmaceutical  and biotechnology

    2.3%

    4.8%Academic

    3.0%

    6.4%Pacific Rim distributors

    10.2%

    4.1%R&D Europe:Reported

    16.2%

    4.4%In constant currency

    3.2%

    4.1%R&D China:Reported

    28.1%

    26.0%In constant currency

    22.2%

    22.6%Hematology net sales for the quarter and fiscal year ended June 30, 2011 were $5.0 million and $19.7 million, increases of 11.9% and 7.0%, respectively, from the comparable prior-year periods.

    The gross margin percentage declined to 76.4% in the quarter ended June 30, 2011 from 79.1% in the comparable prior-year quarter due to costs recognized upon the sale of inventory that was written up to fair value as part of the acquisitions and amortization of intangible assets.  Gross margins were 79.5% and 79.3% for the quarters ended June 30, 2011 and 2010, respectively, if such costs were excluded in both periods.

    Selling, general and administrative expenses for the quarter and fiscal year ended June 30, 2011 increased $3.0 million and $3.2 million from the quarter and fiscal year ended June 30, 2010. The acquired businesses added $945,000 of selling, general and administrative expenses in the quarter and fiscal year, excluding intangible amortization which increased $259,000 in the quarter.  The increase in selling, general and administrative expense for the quarter and fiscal year was also impacted by increased professional fees and costs related to the acquisitions ($1.3 million and $1.7 million for the quarter and fiscal year, respectively) and increased profit sharing expense ($388,000 and $805,000 for the quarter and fiscal year, respectively).

    Foreign exchange transaction gains for the quarter and fiscal year ended June 30, 2011 were $177,000 and $844,000, respectively, compared to foreign exchange transaction losses of $631,000 and $960,000 for the quarter and fiscal year ended June 30, 2010, respectively.

    The effective tax rate for the quarter and fiscal year ended June 30, 2011 was 34.1% and 31.9% as compared to 32.9% and 29.8% for the same prior-year periods. The effective tax rate for the quarter and fiscal year were impacted by non-deductible professional fees and other costs related to the acquisitions, the renewal of the U.S. research and development credit and an increase in the deduction for qualified production activities.  The effective rates for the prior fiscal year were abnormally low due to the tax benefit received following repatriation of funds from the U.K. to the U.S.  Excluding this benefit, the effective tax rates for the fiscal year ended June 30, 2010 would have been 32.8%.  Effective tax rates for fiscal 2012 are expected to be 31% to 33%.

    Forward Looking Statements:

    Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements, including the expected effective tax rate, involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the integration of the acquired companies, the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the retention of hematology OEM and proficiency survey business, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

    For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission.  We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events.  Investors are cautioned not to place undue emphasis on these statements.

    Use of Adjusted Financial Measures:

    The adjusted financial measures used in this press release quantify the impact the following events had on reported net sales, gross margin percentages, selling, general and administrative expenses, effective tax rates, net earnings and earnings per share for the quarter and fiscal year ended June 30, 2011 as compared to the reported amounts for the same periods ended June 30, 2010:

  • fluctuations in exchange rates used to convert transactions in foreign currencies (primarily the Euro, British pound sterling and Chinese yuan) to U.S. dollars,
  • the acquisitions of Boston Biochem on April 1, 2011 and Tocris on April 28, 2011, including the impact of amortizing intangible assets and the recognition of costs upon the sale of inventory written up to fair value, and
  • the tax benefit received following repatriation of cash from the United Kingdom in fiscal 2010.

  • These adjusted financial measures are not prepared in accordance with generally accepted accounting principles (GAAP) and may be different from adjusted financial measures used by other companies.  Adjusted financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.  We view these adjusted financial measures to be helpful in assessing the Company's ongoing operating results.  In addition, these adjusted financial measures facilitate our internal comparisons to historical operating results and comparisons to competitors' operating results.  We include these adjusted financial measures in our earnings announcement because we believe they are useful to investors in allowing for greater transparency related to supplemental information we use in our financial and operational analysis. Investors are encouraged to review the reconciliations of the adjusted financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release.

    Techne Corporation has two operating subsidiaries:  Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty manufacturer of biological products.  R&D Systems has four subsidiaries: BiosPacific, Inc. (BiosPacific), located in Emeryville, California, Boston Biochem, Inc., located in Cambridge, Massachusetts, R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China and Tocris Cookson Inc., located in Saint Louis, Missouri.  BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. Boston Biochem is a leading developer and manufacturer of ubiquitin-related research products. R&D China and R&D Europe distribute biotechnology products.  R&D Europe has two subsidiaries: Tocris Holdings Limited (Tocris) of Bristol, England and R&D Systems GmbH, a German sales operation.  Tocris is a leading supplier of reagents for non-clinical life science research.

    TECHNE CORPORATION

    CONSOLIDATED STATEMENTS OF EARNINGS

    (In thousands, except per share data)

    (Unaudited)QUARTER ENDED

    FISCAL YEAR ENDED6/30/11

    6/30/10

    6/30/11

    6/30/10Net sales

    $78,038

    $66,714

    $289,962

    $269,047Cost of sales

    18,407

    13,943

    65,025

    54,898Gross margin

    59,631

    52,771

    224,937

    214,149Operating expenses:   Selling, general and administrative

    10,562

    7,595

    35,897

    32,700Research and development

    6,466

    6,251

    25,985

    25,121Total operating expenses

    17,028

    13,846

    61,882

    57,821Operating income

    42,603

    38,925

    163,055

    156,328Other income (expense):   Interest income

    818

    1,011

    3,752

    4,375   Other non-operating expense, net

    (450)

    (1,335)

    (1,826)

    (4,257)Total other income (expense)  

    368

    (324)

    1,926

    118Earnings before income taxes

    42,971

    38,601

    164,981

    156,446Income taxes

    14,640

    12,706

    52,679

    46,670Net earnings

    $28,331

    $25,895

    $112,302

    $109,776Earnings per share: Basic

    $   0.76

    $   0.70

    $  3.03

    $  2.95 Diluted

    $   0.76

    $   0.69

    $  3.02

    $   2.94Weighted average common shares outstanding:  Basic

    37,140

    37,233

    37,098

    37,255  Diluted

    37,230

    37,314

    37,172

    37,347TECHNE CORPORATION

    CONSOLIDATED BALANCE SHEETS

    (In thousands)

    (Unaudited)ASSETS

    6/30/11

    6/30/10Cash and equivalents

    $77,613

    $  94,139Short-term available-for-sale investments

    63,200

    44,672Trade accounts receivable

    35,914

    30,850Other receivables

    1,946

    1,532Inventory

    44,906

    13,737Other current assets

    6,838

    16,110  Current assets

    230,417

    201,040Available-for-sale investments

    131,988

    171,171Property and equipment, net

    95,398

    97,400Goodwill and intangible assets, net

    138,915

    27,112Other non-current assets

    20,952

    22,093  Total assets

    $617,670

    $518,816LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities

    $ 18,188

    $  17,024Deferred taxes

    13,360

    0Stockholders' equity

    586,122

    501,792  Total liabilities and stockholders' equity

    $617,670

    $518,816TECHNE CORPORATION

    RECONCILIATION of ORGANIC SALES

    (In thousands)

    (Unaudited)QUARTER ENDED

    FISCAL YEAR ENDED6/30/11

    6/30/10

    6/30/11

    6/30/10Net sales

    $78,038

    $66,714

    $289,962

    $269,047Organic sales adjustments:Acquisitions

    (4,683)

    0

    (4,683)

    0Impact of foreign currency fluctuations

    (2,328)

    0

    (466)

    0Organic sales

    $71,027

    $66,714

    $284,813

    $269,047TECHNE CORPORATION

    RECONCILIATION of NET EARNINGS and EARNINGS per SHARE

    (In thousands, except per share data)

    (Unaudited)QUARTER ENDED

    FISCAL YEAR ENDED6/30/11

    6/30/10

    6/30/11

    6/30/10Net earnings

    $28,331

    $25,895

    $112,302

    $109,776Identified adjustments:Costs recognized upon sale of acquired inventory

    1,835

    0

    1,835

    0Amortization of intangibles

    954

    240

    1,465

    960Professional fees and other acquisition related costs

    1,256

    0

    1,735

    0Tax benefit from repatriation of cash

    0

    0

    0

    (4,660)4,045

    240

    5,035

    (3,700)Tax impact of adjustments

    (797)

    (86)

    (1,119)

    (346)3,248

    154

    3,916

    (4,046)Net earnings – Adjusted for identified items

    $31,579

    $26,049

    $116,218

    $105,730Earnings per share – Diluted – Adjusted

    $   0.85

    $   0.70

    $  3.13

    $   2.83TECHNE CORPORATION

    RECONCILIATION of GROSS MARGIN PERCENTAGES

    (Unaudited)QUARTER ENDED

    FISCAL YEAR ENDED6/30/11

    6/30/10

    6/30/11

    6/30/10Gross margin percentage

    76.4%

    79.1%

    77.6%

    79.6%Identified adjustments:Costs recognized upon sale of acquired inventory

    2.4%

    0.0%

    0.6%

    0.0%Amortization of intangibles

    0.7%

    0.2%

    0.3%

    0.2%Gross margin percentage – Adjusted

    79.5%

    79.3%

    78.5%

    79.8%TECHNE CORPORATION

    RECONCILIATION of SELLING, GENERAL and ADMINISTRATIVE EXPENSES

    (In thousands)

    (Unaudited)QUARTER ENDED

    FISCAL YEAR ENDED6/30/11

    6/30/10

    6/30/11

    6/30/10Selling, general and administrative expenses

    $10,562

    $7,595

    $35,896

    $32,700Identified adjustments:Acquired companies' expense, excluding intangible amortization

    (945)

    0

    (945)

    0Professional fees and other acquisition related costs

    (1,256)

    0

    (1,735)

    0Amortization of intangibles

    (390)

    ( 131)

    (575)

    (525)Selling, general and administrative expenses – Adjusted

    $7,971

    $7,464

    $32,641

    $32,175TECHNE CORPORATION

    RECONCILIATION of EFFECTIVE TAX RATE

    (Unaudited)QUARTER ENDED

    FISCAL YEAR ENDED6/30/11

    6/30/10

    6/30/11

    6/30/10Effective tax rate

    34.1%

    32.9%

    31.9%

    29.8%Identified adjustments:Tax benefit from repatriation of cash

    0.0%

    0.0%

    0.0%

    3.0%Non deductible professional fees and acquisition costs

    (1.1%)

    0.0%

    (0.2%)

    0.0%Effective tax rate – Adjusted

    33.0%

    32.9%

    31.7%

    32.8%TECHNE CORPORATION

    RECONCILIATION of INTANGIBLE AMORTIZATION

    (In thousands)

    (Unaudited)QUARTER ENDED

    FISCAL YEAR ENDED6/30/11

    6/30/10

    6/30/11

    6/30/10Amortization of intangible assets was included in:Cost of goods sold

    $564

    $109

    $890

    $435Selling, general and administrative expenses

    390

    131

    575

    525Total amortization of intangible assets

    $954

    $240

    $1,465

    $960
    '/>"/>

    SOURCE Techne Corporation
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Technest Holdings, Inc. to Acquire AccelPath, LLC; Issue Contingent Value Rights to Common Stockholders; and Issue Shares of Its Series E 5% Convertible Preferred Stock
    2. Techne Corporation Declares Dividend
    3. Techne Corporation Declares Dividend
    4. Upsher-Smith Laboratories Named Manufacturer of the Year by AmerisourceBergen Corporation
    5. Spectros Corporation Year-To-Date Oximeter Sales Revenue Up 51% in First Half of 2011
    6. Kensey Nash Corporation Announces Its Fourth Quarter and Fiscal Year End 2011 Earnings Release Date and Teleconference
    7. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
    8. Vystar® Corporation Spotlights Advantages of Vytex® NRL at the 13th Annual International Latex Conference
    9. CVS Caremark Corporation to Hold Second Quarter 2011 Conference Call
    10. Luminex Corporation Receives U.S. FDA Clearance for New, Front Line Respiratory Viral Panel Test
    11. Biomerix Corporation and Gel Company Announce Strategic Distribution Agreement
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/25/2016)... SPRINGS, Florida , May 25, 2016 ... Business Conference & Expo earlier this month, the numbers ... As revenues continue to climb into the billions, more ... the newly released 4th Edition State of Legal Marijuana ... Frontier, a cannabis-focused data-analysis firm, much of the increase ...
    (Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
    (Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
    Breaking Medicine Technology:
    (Date:5/28/2016)... ... 28, 2016 , ... May 26, 2016- In search of the K. Warriors, ... event of “K Warriors” on June 4, 2016 at Ashbury Hotel and Suites 600 ... sponsored and hosted by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), This ...
    (Date:5/28/2016)... , ... May 28, 2016 , ... In a part of the city where’s it’s ... new farm-to-table Kelowna restaurants is hoping to attract diners with a taste for ... Suites officially opened the doors to Cornerstone Grill, an urban casual restaurant focusing on ...
    (Date:5/27/2016)... ... May 27, 2016 , ... Southland Log Homes , designer ... timber frame barn kits, which can be found on its website at SouthlandLogHomes.com. , ... barn plans, and they highlight the craftsmanship of timber post and beam construction. ...
    (Date:5/27/2016)... ... May 27, 2016 , ... W.S. Badger Co. ... today that it has been recognized as one of the best small businesses for ... named as one of nine small businesses providing progressive benefits to new parents on ...
    (Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent ... the demand for a sustainable product to aid in the rehabilitation process has steadily ... the recovery of individuals with hemiplegia due to stroke. , Ekso Bionics has now ...
    Breaking Medicine News(10 mins):